About Atomoxetine Hydrochloride API
Therapeutic CategoryCentral Nervous System (CNS)
CAS Number
82248-59-7
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Canada DMF
Mechanism of Action
The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.
Indication
STRATTERA is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Related APIs
Eslicarbazepine Acetate
Central Nervous System (CNS)
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!